AbbVie's Maviret ends the wait-and-see reality for acute HCV

AbbVie's Maviret became the first therapy approved in the EU for both acute and chronic hepatitis C virus (HCV), removing the previous requirement to confirm chronic infection before starting treatment. This regulatory update aligns drug indications with clinical guidelines and aims to accelerate treatment, reducing transmission risks and supporting HCV elimination efforts.

This Wire brief sits within Fusion42's coverage of Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.